Dynavax Tender Offer Expires, Minimum Condition Met, Merger to Finalize

summarizeSummary

Dynavax Technologies announced the successful expiration of Sanofi's tender offer, with 73.92% of shares tendered, satisfying the minimum condition and paving the way for a short-form merger.

check_boxKey Events

• Tender Offer Expired

  Sanofi's tender offer for Dynavax shares expired on February 9, 2026, as scheduled, and was not extended.

• Minimum Condition Met

  A total of 84,680,752 shares, representing approximately 73.92% of outstanding shares, were validly tendered, satisfying the minimum condition for the merger.

• Shares Accepted for Payment

  Purchaser has irrevocably accepted all validly tendered shares for payment.

• Merger to Finalize via Short-Form Process

  The acquisition will be completed through a short-form merger under Section 251(h) of the DGCL, without a meeting of Dynavax stockholders.

auto_awesomeAnalysis

This filing provides the definitive update on the acquisition of Dynavax Technologies by Sanofi, following the initial announcement on January 12, 2026. The successful completion of the tender offer, with a significant majority of shares tendered, confirms that the merger will proceed via a short-form process without a shareholder meeting. This marks the final stage of Dynavax's existence as an independent public company, with its shares expected to be delisted from Nasdaq following the merger. Investors should be aware that the company will soon cease to trade publicly.